|
[posting]43247107[/posting]Nur mal zur Anregung, auch Seite 11 Quartalsbericht....geht dann noch weiter.... . . . According to another agreement entered among the Company and certain investors, the conversion price of the Company’s convertible notes, and the exercise price of the September 2011 Warrants, the December 2010 Warrants, defined below, and the March 2010 Warrants, defined below, were reset to $0.001 effective December 17, 2011. The conversion price reset on all of the Company’s convertible notes resulted in a full debt discount being recorded in an amount equal to the face value of the Company’s convertible notes on December 17, 2011. The Company is amortizing the resultant debt discounts over the terms of the notes through their maturity dates. On December 19, 2011, three holders of September 2011 Debt Warrants totaling $2.9 million, exercised their warrants using a cashless exercise procedure and received September 2011 G Notes for $2.1 million. The aggregate intrinsic value of the difference between the market price of a share of the Company’s stock on December 19, 2011 and the conversion price of the notes was in excess of the face value of the September 2011 G Notes of $2.1 million, and a full debt discount was recorded in an amount equal to the face value of the notes. The Company is amortizing the resultant debt discount over the term of the notes through their maturity date. The September 2011 Warrants and the September 2011 Debt Warrants both have anti-dilution protection and can be exercised using a cashless exercise procedure; warrants with these characteristics are accounted for as liabilities and marked-to-market over their lives. At March 31, 2012, the September 2011 Warrants and the September 2011 Debt Warrants were re-measured, in total, at $11.6 million based upon a Black-Scholes valuation model, resulting in income of $24.2 million on the Condensed Consolidated Statement of Operations for the three-month period ended March 31, 2012. The September 2011 Warrants were valued at March 31, 2012 and December 31, 2011 using a Black-Scholes valuation model with the following assumptions: . . . http://www.sec.gov/Archives/edgar/data/880643/00014377491200… |
|
| aus der Diskussion: | Genta - Revolution in der Krebstherapie? |
| Autor (Datum des Eintrages): | auriga (04.06.12 16:33:11) |
| Beitrag: | 55,037 von 55,414 (ID:43247327) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |